Johannes Vermehren
Overview
Explore the profile of Johannes Vermehren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon K, et al.
Z Gastroenterol
. 2020 Sep;
58(9):841-846.
PMID: 32947629
Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was...
12.
Graf C, Welzel T, Bogdanou D, Vermehren J, Beckel A, Bojunga J, et al.
J Clin Med
. 2020 Aug;
9(9).
PMID: 32825571
Background: Chronic hepatitis C virus (HCV) infections are causally linked with metabolic comorbidities such as insulin resistance, hepatic steatosis, and dyslipidemia. However, the clinical impact of HCV eradication achieved by...
13.
De Salazar A, Dietz J, Di Maio V, Vermehren J, Paolucci S, Mullhaupt B, et al.
J Antimicrob Chemother
. 2020 Aug;
75(11):3349-3358.
PMID: 32772078
Objectives: To investigate resistance-associated substitutions (RASs) as well as retreatment efficacies in a large cohort of European patients with failure of glecaprevir/pibrentasvir. Methods: Patients were identified from three European Resistance...
14.
Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, et al.
Liver Int
. 2020 Jul;
PMID: 32640072
Background&aims: The presence of baseline resistance-associated substitutions (RASs) reduced sustained virologic response (SVR) rates in chronic hepatitis C virus (HCV) genotype 1a infected patients treated with Elbasvir/Grazoprevir (EBR/GZR). This study...
15.
Koch C, Bette T, Waidmann O, Filmann N, Schrecker C, Trojan J, et al.
PLoS One
. 2020 Jul;
15(7):e0235576.
PMID: 32614912
Background/aims: Hepatocellular carcinoma (HCC) is a leading indication for liver transplantation (LT) worldwide. Early identification of patients at risk for HCC recurrence is of paramount importance since early treatment of...
16.
Dietz J, Kalinina O, Vermehren J, Peiffer K, Matschenz K, Buggisch P, et al.
J Viral Hepat
. 2020 May;
27(10):974-986.
PMID: 32396998
Data on the prevalence of resistance-associated substitutions (RASs) and their implications for treatment with direct-acting antivirals (DAAs) are sparse in European patients with HCV genotype 4. This study investigated RASs...
17.
Cheng X, Uchida T, Xia Y, Umarova R, Liu C, Chen P, et al.
J Clin Invest
. 2020 Mar;
130(6):3205-3220.
PMID: 32163375
In patients with HBV and HCV coinfection, HBV reactivation leading to severe hepatitis has been reported with the use of direct-acting antivirals (DAAs) to treat HCV infection. Here we studied...
18.
Schmitt A, Gunther R, Mauss S, Boeker K, Buggisch P, Hillenbrand H, et al.
Z Gastroenterol
. 2020 Feb;
58(4):341-351.
PMID: 32040979
Background: Virologic failure to approved combinations of direct antiviral agents (DAA) in patients with chronic hepatitis C virus (HCV) infection is rare. Mostly it involves difficult to treat patients with...
19.
Graf C, Mondorf A, Knop V, Peiffer K, Dietz J, Friess J, et al.
J Clin Med
. 2019 Dec;
8(12).
PMID: 31810183
Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral...
20.
Mucke M, Maasoumy B, Dietz J, Mucke V, Simon C, Canchola J, et al.
PLoS One
. 2019 Nov;
14(11):e0224751.
PMID: 31738773
Background: The COBAS AmpliPrep/COBAS TaqMan assay HCV (CAP/CTM) is widely used in clinical routine for HCV testing. Recently, the new cobas HCV test was established for high throughput testing with...